22 July 2024
Baker McKenzie advises the shareholders of APEIRON Biologics AG on the sale of their shares to an American investor
Advising firms
Deal team
1 lawyer named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Gerhard Hermann Lead | Baker McKenzie | Partner | M&A | Not stated |
Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- shareholders of APEIRON Biologics AGSell-side
- Counterparties
- Ligand Pharmaceuticals Incorporated (Buy-side)